C5AR1 and early-onset autosomal dominant Alzheimer disease: In addition, pharmacological inhibition of C5a-C5aR1 signaling with a C5aR1 antagonist (PMX205) in two different mouse models of Alzheimer’s disease (the Tg2576 and the 3xTgAD mouse models) resulted in a significant reduction of the neuropathology associated with AD as well as an improvement of memory and cognition [22], further supporting the targeted inhibition of C5aR1 as a potential therapeutic strategy for AD.